News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Probiomics Limited: New Australian Drug Developer Lists on ASX



4/4/2012 9:32:30 AM

SYDNEY--(BUSINESS WIRE)--Following the merger of private drug developer Hunter Immunology Limited with Probiomics Limited (ASX: PCC), the merged entity today recommenced trading on the Australian Securities Exchange (ASX). The business will initially continue to trade as and intends to rename as Bioxyne (ASX: BXN) in coming weeks. At the commencement of trading, the company had a market cap of over $33 million with 149.9 million shares.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES